JP2009543867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543867A5 JP2009543867A5 JP2009520780A JP2009520780A JP2009543867A5 JP 2009543867 A5 JP2009543867 A5 JP 2009543867A5 JP 2009520780 A JP2009520780 A JP 2009520780A JP 2009520780 A JP2009520780 A JP 2009520780A JP 2009543867 A5 JP2009543867 A5 JP 2009543867A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- phenyl
- substituted
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 114
- 125000001424 substituent group Chemical group 0.000 claims 98
- 125000000623 heterocyclic group Chemical group 0.000 claims 83
- 125000001072 heteroaryl group Chemical group 0.000 claims 76
- 229910052799 carbon Inorganic materials 0.000 claims 55
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 125000005843 halogen group Chemical group 0.000 claims 41
- 229910052731 fluorine Inorganic materials 0.000 claims 40
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 31
- 229910052794 bromium Inorganic materials 0.000 claims 29
- 125000004043 oxo group Chemical group O=* 0.000 claims 29
- 229910052801 chlorine Inorganic materials 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 125000002757 morpholinyl group Chemical group 0.000 claims 22
- 125000003386 piperidinyl group Chemical group 0.000 claims 22
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 22
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000004193 piperazinyl group Chemical group 0.000 claims 21
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 125000004076 pyridyl group Chemical group 0.000 claims 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 15
- -1 O-C 1 -C 6 Haloalkyl Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 125000001272 (C1-C4)-alkylene-phenyl group Chemical group 0.000 claims 12
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 12
- 125000002883 imidazolyl group Chemical group 0.000 claims 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001544 thienyl group Chemical group 0.000 claims 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000002541 furyl group Chemical group 0.000 claims 9
- 125000000335 thiazolyl group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000002971 oxazolyl group Chemical group 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 7
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010002459 HIV Integrase Proteins 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 3
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical group [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 0 *N(CC1)CC2=C1N=ICC2 Chemical compound *N(CC1)CC2=C1N=ICC2 0.000 description 3
- NKWOXRUJRCMCBH-UHFFFAOYSA-N NN(C1)Cc2c1cccc2 Chemical compound NN(C1)Cc2c1cccc2 NKWOXRUJRCMCBH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83141506P | 2006-07-17 | 2006-07-17 | |
| PCT/US2007/016052 WO2008010964A1 (en) | 2006-07-17 | 2007-07-13 | 1-hydroxy naphthyridine compounds as anti-hiv agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543867A JP2009543867A (ja) | 2009-12-10 |
| JP2009543867A5 true JP2009543867A5 (enExample) | 2010-08-12 |
Family
ID=38957074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520780A Withdrawn JP2009543867A (ja) | 2006-07-17 | 2007-07-13 | 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100056516A1 (enExample) |
| EP (1) | EP2044068A4 (enExample) |
| JP (1) | JP2009543867A (enExample) |
| AU (1) | AU2007275816A1 (enExample) |
| CA (1) | CA2657287A1 (enExample) |
| WO (1) | WO2008010964A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| WO2011057989A1 (en) * | 2009-11-11 | 2011-05-19 | Basf Se | Heterocyclic compounds having herbicidal action |
| WO2012058173A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| FR2970967B1 (fr) | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| US20140369934A1 (en) | 2011-06-02 | 2014-12-18 | Massachusetts Institute Of Technology | dsRNA/DNA Hybrid Genome Replication Intermediate Of Metakaryotic Stem Cells |
| WO2013049332A1 (en) * | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2013115265A1 (ja) * | 2012-01-31 | 2013-08-08 | 富山化学工業株式会社 | 抗ｈｉｖ活性を有する複素環化合物 |
| WO2013165898A2 (en) * | 2012-05-01 | 2013-11-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting resolvases |
| EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| EA028402B1 (ru) * | 2012-12-24 | 2017-11-30 | Кадила Хелзкэр Лимитед | Хинолоновые производные |
| US9676771B2 (en) * | 2013-05-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for inhibiting drug-resistant strains of HIV-1 integrase |
| HUE045511T2 (hu) | 2014-02-03 | 2020-01-28 | Vitae Pharmaceuticals Llc | A ror-gamma dihidro-pirrolopiridin inhibitorai |
| CN111909130B (zh) * | 2014-09-19 | 2023-10-31 | 福马治疗股份有限公司 | 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 |
| AU2015317321B2 (en) | 2014-09-19 | 2020-03-12 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| CN108463458B (zh) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | ROR-γ的调节剂 |
| CN105418609B (zh) * | 2015-12-31 | 2017-06-23 | 山东大学 | 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| JP7453399B2 (ja) | 2020-02-24 | 2024-03-19 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ感染症を治療するための四環式化合物及びその使用 |
| WO2022072520A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| PT4196479T (pt) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | Compostos de piridotriazinas substituídos e suas utilizações |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| KR20250128292A (ko) | 2022-09-26 | 2025-08-27 | 엣지와이즈 테라퓨틱스, 인크. | 1,4-디하이드로퀴나졸리논 화합물 및 이의 용도 |
| WO2024206339A1 (en) * | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527819A (en) * | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| GB9420168D0 (en) * | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| US6306891B1 (en) * | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6380249B1 (en) * | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6262055B1 (en) * | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| EP1196384A4 (en) * | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS |
| AU1532802A (en) * | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| JP2004517860A (ja) * | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
| JP4252797B2 (ja) * | 2000-10-12 | 2009-04-08 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
| CA2425067A1 (en) * | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| ES2572030T3 (es) * | 2001-08-10 | 2017-07-19 | Shionogi & Co., Ltd. | Agente antiviral |
| ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| DE60209381T2 (de) * | 2001-10-26 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase |
| DE60315796T2 (de) * | 2002-01-17 | 2008-06-05 | Merck & Co., Inc. | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| WO2004004657A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| EP2045242A1 (en) * | 2002-08-13 | 2009-04-08 | Shionogi&Co., Ltd. | Heterocyclic compounds having inhibitory activity against HIV integrase |
| US20040162285A1 (en) * | 2002-11-01 | 2004-08-19 | Pratt John K. | Anti-infective agents |
| US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
| US7501503B2 (en) * | 2002-12-31 | 2009-03-10 | Mcgill University | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
| WO2005090316A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | HYDANTOINS HAVING RNase MODULATORY ACTIVITY |
| US20050203176A1 (en) * | 2004-03-12 | 2005-09-15 | Wyeth | Carbamates as HIV anti-viral agents |
| WO2005090309A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | 1,2-dihydroquinoline derivatives and method for using the same to treat hiv infection |
-
2007
- 2007-07-13 CA CA002657287A patent/CA2657287A1/en not_active Abandoned
- 2007-07-13 AU AU2007275816A patent/AU2007275816A1/en not_active Abandoned
- 2007-07-13 EP EP07796862A patent/EP2044068A4/en not_active Withdrawn
- 2007-07-13 JP JP2009520780A patent/JP2009543867A/ja not_active Withdrawn
- 2007-07-13 WO PCT/US2007/016052 patent/WO2008010964A1/en not_active Ceased
- 2007-07-13 US US12/373,907 patent/US20100056516A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543867A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| RU2481346C2 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| JP2012528166A5 (enExample) | ||
| JP2007528379A5 (enExample) | ||
| JP2007512349A5 (enExample) | ||
| JP2008538750A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| JP2009536620A5 (enExample) | ||
| RU2018121499A (ru) | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 | |
| JP2013507425A5 (enExample) | ||
| JP2012511588A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| NO20071234L (no) | Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin | |
| JP2014506599A5 (enExample) | ||
| HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
| JP2018525375A5 (enExample) | ||
| JP2006514691A5 (enExample) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| RU2011100786A (ru) | Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2014525420A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| AR056206A1 (es) | Pirazolpirimidinas como inhibidores de protein quinasas | |
| JP2017505762A5 (enExample) |